Cortistatin-17 (human) peptide

Cortistatin-17 (human) peptide

• COA/MS/HPLC Report
• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

DRMPCRNFFWKTFSSCK (Disulfide bridge: Cys5-Cys16)

H-Asp-Arg-Met-Pro-Cys-Arg-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Ser-Ser-Cys-Lys-OH (Disulfide bridge: Cys5-Cys16)

17

95.22%

C₉₆H₁₃₉N₂₇O₂₄S₃

2151.53

189450-19-9

Synthetic

Powder

This peptide with structural similarities to somatostatin binds to all somatostatin receptor subtypes (SSTR) in a similar way as the rat cortistatin. Its inhibitory effects on forskolin-stimulated cAMP production in chinese hamster ovary cells expressing SSTR2-5 are dose dependent but slightly less efficient than that of somatostatin-14. Like the rat cortistatin it has an effect on sleep and wakefulness pattern in rat. It decreases the light slow wave sleep (SWS1) and increases the deep slow wav

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual:Handling and Storage of Synthetic Peptides

• L.de Lecea, Genomics, 42, 499 (1997)
• S.Fukusumi et al., Biochem. Biophys. Res. Commun., 232, 157 (1997)
• Clynen E, Swijsen A, Raijmakers M, Hoogland G, Rigo JM. Neuropeptides as targets for the development of anticonvulsant drugs. Mol Neurobiol. 2014 Oct;50(2):626-46. doi: 10.1007/s12035-014-8669-x. Epub 2014 Apr 6. PMID: 24705860; PMCID: PMC4182642.

Trifluoroacetic acid (TFA) has a significant impact on peptides due to its role in the peptide synthesis process.

TFA is essential for the protonation of peptides that lack basic amino acids such as Arginine (Arg), Histidine (His), and Lysine (Lys), or ones that have blocked N-termini. As a result, peptides often contain TFA salts in the final product.

TFA residues, when present in custom peptides, can cause unpredictable fluctuations in experimental data. At a nanomolar (nM) level, TFA can influence cell experiments, hindering cell growth at low concentrations (as low as 10 nM) and promoting it at higher doses (0.5–7.0 mM). It can also serve as an allosteric regulator on the GlyR of glycine receptors, thereby increasing receptor activity at lower glycine concentrations.

In an in vivo setting, TFA can trifluoroacetylate amino groups in proteins and phospholipids, inducing potentially unwanted antibody responses. Moreover, TFA can impact structure studies as it affects spectrum absorption.